Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04670913
Status:
UNKNOWN
Last Update Posted:
2021-06-29
First Post:
2020-11-26
Brief Title:
Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy
Sponsor:
Junling Li
Organization:
Peking Union Medical College
Organization Data
Organization:
Peking Union Medical College
Class:
OTHER
Study ID:
NCC2607
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Junling Li
Lead Sponsor Class:
OTHER
Responsible Party:
Junling Li
Responsible Party Title:
Prof Junling Li Chief Physician Medical Doctor PhD Tutor Internal Medicine-Oncology Chinese Academy of Medical Sciences Cancer Hospital
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Peking Union Medical College
Old Name:
None
Old Organization:
None